69938-07-4 Usage
Uses
Used in Medical Research:
Alpha-monofluoromethyldopa is utilized as a research compound for studying the neurobiology of neuropsychiatric disorders such as depression and schizophrenia. Its structural similarity to dopamine allows it to be used in PET imaging to visualize and analyze the activity of dopamine receptors in the brain.
Used in Neurological and Psychiatric Diagnosis:
alpha-monofluoromethyldopa is being explored for its potential in diagnosing various neurological and psychiatric conditions. Its ability to be labeled with fluorine for PET imaging aids in the detection and monitoring of these disorders by providing detailed insights into the brain's neurochemical pathways.
Used in Enhancing Understanding of Neurochemical Pathways:
Alpha-monofluoromethyldopa contributes to the advancement of knowledge regarding the neurochemical pathways involved in mood and cognitive function. Its unique properties as a fluorinated compound enable researchers to track and label dopamine receptor activity, thus enhancing the comprehension of the underlying mechanisms in neuropsychiatric conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 69938-07-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,9,3 and 8 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 69938-07:
(7*6)+(6*9)+(5*9)+(4*3)+(3*8)+(2*0)+(1*7)=184
184 % 10 = 4
So 69938-07-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H12FNO4/c11-5-10(12,9(15)16)4-6-1-2-7(13)8(14)3-6/h1-3,13-14H,4-5,12H2,(H,15,16)/t10-/m1/s1
69938-07-4Relevant academic research and scientific papers
Fluorinated amino acids
-
, (2008/06/13)
Novel substituted α-fluoromethyl-α-amino alkanoic acids and esters thereof are disclosed. The novel compounds have biological activity including decarboxylase inhibition.
Process for preparing fluorinated amino-nitriles
-
, (2008/06/13)
Certain α-(fluoromethyl or difluoromethyl)-α-aminoacetonitriles are prepared by treating the appropriate α-(fluoromethyl or difluoromethyl) ketimine magnesium halide with hydrogen cyanide or with an alkali metal cyanide or ammonium cyanide and a proton source. The products are useful as intermediates for making α-(fluoromethyl or difluoromethyl)-α-amino acids having pharmacological activity.
Method of depleting endogenous monoamines
-
, (2008/06/13)
2-Amino-2-fluoromethyl-3-(substituted)phenyl propionic acids and derivatives thereof are coadministered with dopamine for the treatment of schizophrenia, mania, tardive dyskinesia, anxiety, or depression.
Fluorinated amino acids
-
, (2008/06/13)
Novel substituted α-fluoromethyl-α-amino alkanoic acids and esters thereof are disclosed. The novel compounds have biological activity including decarboxylase inhibition.
